Filing Details
AN2 Therapeutics, Inc. (NASDAQ:ANTX) filed a Form 8-K with the Securities and Exchange Commission on November 09, 2026, disclosing a material event.
8k filedNASDAQ:ANTX
AN2 Therapeutics, Inc. (ANTX) Reports Material Event to SEC
AN2 Therapeutics, Inc. (NASDAQ:ANTX) filed a Form 8-K with the Securities and Exchange Commission on November 09, 2026, disclosing a material event.
At publication ·
What changed
AN2 Therapeutics, Inc. (NASDAQ:ANTX) · 8k filed
- Form
- 8-K
At a glance
Key takeaways
- AN2 Therapeutics filed a Form 8-K on November 09, 2026, disclosing a material event that shareholders should know about.
- The company's stock trades at $4.00 with a market capitalization of $30.1M.
- Material events in 8-K filings can include leadership changes, agreements, acquisitions, asset sales, or financial guidance changes.
Market Context
AN2 Therapeutics, Inc.'s stock currently trades at $4.00 with a market capitalization of $30.1M. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for AN2 Therapeutics, Inc.'s stock.
All SEC filings for AN2 Therapeutics, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View ANTX Stock Page
Frequently Asked Questions
Where can I read ANTX's SEC filings?
Browse all filings on our ANTX SEC filings page.
What types of SEC filings does AN2 Therapeutics, Inc. file?
Public companies like AN2 Therapeutics, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.